Imagining a role for psychedelics in dementia care
Despite being banned in the 1970s,1 psychedelics are experiencing a cultural renaissance, with growing evidence suggesting compounds like psilocybin, MDMA, LSD, and ketamine may be effective therapies in controlled medical settings.2 Researchers have observed particular benefits for psychedelics in treatment of refractory depression, anxiety, substance addiction (tobacco/alcohol), PTSD, and in palliative care for patients facing terminal cancer.3,4
Source: The American Journal of Geriatric Psychiatry - Category: Geriatrics Authors: Daniel R. George, Ryan Hanson Source Type: research
More News: Addiction | Alcoholism | Anxiety | Cancer | Cancer & Oncology | Dementia | Depression | Geriatrics | Palliative | Palliative Care | Post Traumatic Stress Disorder | Psychiatry | Smokers